BIOQ (Bioqual) Other Stockholders Equity: $-0.00 Mil (As of Nov. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOQ Bioqual Inc BIOQ
54 GF Score
Price $33.00
! 4 Warning Signs
View Full Analysis

What is Bioqual Other Stockholders Equity?

Bioqual BIOQ 54 Other Stockholders Equity is $-0.00 Mil as of Nov. 2025. GuruFocus rates BIOQ with a GF Score™ of 54/100. The stock has 4 warning signs investors should review.

Bioqual's Other Stockholders Equity for the quarter that ended in Nov. 2025 was $-0.00 Mil.

Bioqual's quarterly Other Stockholders Equity declined from Nov. 2024 ($0.00 Mil) to Aug. 2025 ($-0.00 Mil) and declined from Aug. 2025 ($-0.00 Mil) to Nov. 2025 ($-0.00 Mil).

Bioqual's annual Other Stockholders Equity increased from May. 2011 ($-0.00 Mil) to May. 2017 ($0.00 Mil) but then stayed the same from May. 2017 ($0.00 Mil) to May. 2018 ($0.00 Mil).

Bioqual Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Bioqual's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioqual Other Stockholders Equity Chart

Bioqual Annual Data
Trend May01 May03 May04 May05 May06 May07 May10 May11 May17 May18
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00

Bioqual Quarterly Data
Aug06 Nov06 Feb07 May07 Nov09 Feb10 May10 Aug10 Nov10 Feb11 May11 Aug11 May17 May18 Aug22 Aug23 Aug24 Nov24 Aug25 Nov25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 -0.00 -0.00
BIOQ
54GF Score
Bioqual Inc BIOQ
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioqual Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
Bioqual (BIOQ) has a Other Stockholders Equity of $-0.00 Mil as of Nov. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bioqual and its competitors.
Is Bioqual's Other Stockholders Equity too high?
Bioqual's current Other Stockholders Equity is $-0.00 Mil. Overall, Bioqual has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Bioqual's Other Stockholders Equity compare to ADVB and QUCY?
Bioqual's Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Diagnostics & Research company?
A good Other Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bioqual and its competitors. Bioqual's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioqual stock overvalued right now?
Bioqual (BIOQ) has a current Other Stockholders Equity of $-0.00 Mil. The current Other Stockholders Equity is $-0.00 Mil. Bioqual's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Bioqual (BIOQ), the current Other Stockholders Equity is $-0.00 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioqual Business Description

Address 9620 Medical Center Drive, Suite 310, Rockville, MD, USA, 20850
Bioqual Inc is a United States-based medical research company. It is engaged in providing contract research services focused on animal models of human diseases, including AIDS, influenza, RSV infection, flavivirus infections like Zika and Dengue, malaria, hepatitis, and cancer. The company is also involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. It provides services to the federal government, universities, and the life science and pharmaceutical industries. It derives revenue from the provision of contract research services.
54GF Score

Get the complete analysis for BIOQ

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.00
Price